首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and biological activities of drugs for the treatment of osteoporosis
【24h】

Synthesis and biological activities of drugs for the treatment of osteoporosis

机译:骨质疏松症治疗药物的合成与生物学活性

获取原文
获取原文并翻译 | 示例
           

摘要

Osteoporosis is an asymptomatic progressive disease. With the improvement of people's living standard and the aging of population, osteoporosis and its fracture have become one of the main diseases threatening the aging society. The serious medical and social burden caused by this has aroused wide public concern. Osteoporosis is listed as one of the three major diseases of the elderly. At present, the drugs for osteoporosis include bone resorption inhibitors and bone formation promoters. The purpose of these anti-osteoporosis drugs is to balance osteoblast bone formation and osteoclast bone resorption. With the development of anti-osteoporosis drugs, new anti osteoporosis drugs have been designed and synthesized. There are many kinds of new compounds with anti osteoporosis activity, but most of them are concentrated on the original drugs with anti osteoporosis activity, or the natural products with anti-osteoporosis activity are extracted from the natural products for structural modification to obtain the corresponding derivatives or analogues. These target compounds showed good ALP activity in vitro and in vivo, promoted osteoblast differentiation and mineralization, or had anti TRAP activity, inhibited osteoclast absorption. This work attempts to systematically review the studies on the synthesis and bioactivity of anti-osteoporosis drugs in the past 10 years. The structure-activity relationship was discussed, which provided a reasonable idea for the design and development of new anti-osteoporosis drugs. (C) 2020 Elsevier Masson SAS. All rights reserved.
机译:骨质疏松症是一种无症状的渐进性疾病。随着人们生活水平的改善和人口老化,骨质疏松症及其骨折已成为威胁老龄化社会的主要疾病之一。由此引起的严重医疗和社会负担引起了广泛的公众关注。骨质疏松症被列为老年人的三种主要疾病之一。目前,骨质疏松症的药物包括骨吸收抑制剂和骨形成启动子。这些抗骨质疏松症药物的目的是平衡成骨细胞骨形成和破骨细胞骨吸收。随着抗骨质疏松药物的发展,已经设计和合成了新的抗骨质疏松症药物。有许多类型的新化合物具有抗骨质疏松症活性,但大多数集中在具有抗骨质疏松活性的原有的药物上,或者从天然产物中提取抗骨质疏松活性的天然产物进行结构改性以获得相应的衍生物或类似物。这些目标化合物在体外和体内显示出良好的AlP活性,促进成骨细胞分化和矿化,或具有抗捕集活性,抑制破骨细胞吸收。这项工作试图系统地检讨过去10年来彻底审查抗骨质疏松症药物的合成和生物活性的研究。讨论了结构 - 活动关系,为新的抗骨质疏松症药物的设计和开发提供了合理的理念。 (c)2020 Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号